ConductScience.org, home
A Safety and Tolerability Study of Assisted and Self-Administered Subcutaneous (SC) Herceptin (Trastuzumab) as Adjuvant Therapy in Early Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer
API referenceFor AI assistants

Trial · NCT01566721

Adverse events1,556

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

1 to 20 of 1,556

Download this page as JSON
TypeEventOrgan systemGroupAffectedAt riskEvents
otherFatigueGeneral disordersCohort A: SC Herceptin by Needle/Syringe3811,864
otherFatigueGeneral disordersCohort B: SC Herceptin by SID132709
otherFatigueGeneral disordersCohort A: SC Herceptin by Needle/Syringe Safety Follow-up01,862
otherFatigueGeneral disordersCohort B: SC Herceptin by SID Safety Follow-up0707
otherAstheniaGeneral disordersCohort A: SC Herceptin by Needle/Syringe2211,864
otherAstheniaGeneral disordersCohort B: SC Herceptin by SID85709
otherAstheniaGeneral disordersCohort A: SC Herceptin by Needle/Syringe Safety Follow-up01,862
otherAstheniaGeneral disordersCohort B: SC Herceptin by SID Safety Follow-up0707
otherPyrexiaGeneral disordersCohort A: SC Herceptin by Needle/Syringe1851,864
otherPyrexiaGeneral disordersCohort B: SC Herceptin by SID55709
otherPyrexiaGeneral disordersCohort A: SC Herceptin by Needle/Syringe Safety Follow-up01,862
otherPyrexiaGeneral disordersCohort B: SC Herceptin by SID Safety Follow-up0707
otherOedema peripheralGeneral disordersCohort A: SC Herceptin by Needle/Syringe1601,864
otherOedema peripheralGeneral disordersCohort B: SC Herceptin by SID45709
otherOedema peripheralGeneral disordersCohort A: SC Herceptin by Needle/Syringe Safety Follow-up01,862
otherOedema peripheralGeneral disordersCohort B: SC Herceptin by SID Safety Follow-up0707
otherInjection site erythemaGeneral disordersCohort A: SC Herceptin by Needle/Syringe1281,864
otherInjection site erythemaGeneral disordersCohort B: SC Herceptin by SID52709
otherInjection site erythemaGeneral disordersCohort A: SC Herceptin by Needle/Syringe Safety Follow-up01,862
otherInjection site erythemaGeneral disordersCohort B: SC Herceptin by SID Safety Follow-up0707

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Next page

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT01566721/events

API referenceFor AI assistants